The effect of cessation of growth hormone (GH) therapy on bone mineral accretion in GH-deficient adolescents at the completion of linear growth.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

In many countries, treatment of childhood-onset GH deficiency (GHD) with GH ceases when linear growth is complete.

Peak bone mass occurs several years after the completion of linear growth.

Who Took Part

The study group was 24 adolescents.

PubMed indexes the participants as teenagers and adults, both men and women.

How the Study Was Run

In design terms this was a randomized and multicenter study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Running at several centres spread the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study over different clinics and patient groups.

Markers of bone remodeling (serum bone-specific alkaline phosphatase and urinary deoxypyridinoline) were measured at the same time points.

What Was Measured

Topics PubMed links to this paper include Alkaline Phosphatase, Amino Acids, Biomarkers, Body Height, Bone Density, Bone Remodeling and Calcification, Physiologic.

What This Means in Plain Language

The paper is a randomized and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 24 adolescents.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2003 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.